

An osmotic laxative renders mice susceptible to prolonged *Clostridioides difficile* colonization and hinders clearance

Sarah Tomkovich¹, Ana Taylor¹, Jacob King¹, Joanna Colovas¹, Lucas Bishop¹, Kathryn McBride¹, Sonya Royzenblat¹, Nicholas A. Lesniak¹, Ingrid L. Bergin², Patrick D. Schloss^{1†}

† To whom correspondence should be addressed: pschloss@umich.edu

1. Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA
2. The Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI, USA

1 Abstract

2 Antibiotics are a major risk factor for *Clostridioides difficile* infections (CDIs) because of their
3 impact on the microbiota. However, non-antibiotic medications such as the ubiquitous osmotic
4 laxative polyethylene glycol (PEG) 3350 also alter the microbiota. Clinicians also hypothesize
5 that PEG helps clear *C. difficile*. But whether PEG impacts CDI susceptibility and clearance is
6 unclear. To examine how PEG impacts susceptibility, we treated C57Bl/6 mice with 5-day and
7 1-day doses of 15% PEG in the drinking water and then challenged the mice with *C. difficile*
8 630. We used clindamycin-treated mice as a control because they consistently clear *C. difficile*
9 within 10 days post-challenge. PEG treatment alone was sufficient to render mice susceptible
10 and 5-day PEG-treated mice remained colonized for up to 30 days post-challenge. In contrast,
11 1-day PEG treated mice were transiently colonized, clearing *C. difficile* within 7 days post-challenge.
12 To examine how PEG treatment impacts clearance, we administered a 1-day PEG treatment
13 to clindamycin-treated, *C. difficile*-challenged mice. Administering PEG to mice after *C. difficile*
14 challenge prolonged colonization up to 30 days post-challenge. When we trained a random
15 forest model with community data from 5 days post-challenge, we were able to predict which
16 mice would exhibit prolonged colonization (AUROC = 0.90). Examining the dynamics of these
17 bacterial populations during the post-challenge period revealed patterns in the relative abundances
18 of *Bacteroides*, *Enterobacteriaceae*, *Porphyromonadaceae*, *Lachnospiraceae*, and *Akkermansia*
19 that were associated with prolonged *C. difficile* colonization in PEG-treated mice. Thus, the osmotic
20 laxative, PEG, rendered mice susceptible to *C. difficile* colonization and hindered clearance.

21 Importance

22 Diarrheal samples from patients taking laxatives are typically rejected for *Clostridioides difficile*
23 testing. However, there are similarities between the bacterial communities from people with diarrhea
24 or *C. difficile* infections (CDI) including lower diversity compared to communities from healthy
25 patients. This observation led us to hypothesize that diarrhea may be an indicator of *C. difficile*
26 susceptibility. We explored how osmotic laxatives disrupt the microbiota's colonization resistance to
27 *C. difficile* by administering a laxative to mice either before or after *C. difficile* challenge. Our findings
28 suggest that osmotic laxatives disrupt colonization resistance to *C. difficile*, and prevent clearance

29 among mice already colonized with *C. difficile*. Considering that most hospitals recommend not
30 performing *C. difficile* testing on patients taking laxatives and laxatives are prescribed prior to
31 administering fecal microbiota transplants via colonoscopy to patients with recurrent CDIs, further
32 studies are needed to evaluate if laxatives impact microbiota colonization resistance in humans.

33 **Introduction**

34 Antibiotics are a major risk factor for *Clostridioides difficile* infections (CDIs) because they disrupt
35 microbiota colonization resistance (1). However, antibiotics are not the only types of medications
36 that disrupt the microbiota (2–4). Although, other medications (proton pump inhibitors, osmotic
37 laxatives, antimotility agents, and opioids) have been implicated as risk or protective factors for CDIs
38 through epidemiological studies, whether the association is due to their impact on the microbiota is
39 still unclear (5–9).

40 Many of the non-antibiotic medications associated with CDIs are known to modulate gastrointestinal
41 motility leading to either increased or decreased colonic transit time, which in turn also strongly
42 impacts microbiota composition and function (10, 11). Stool consistency often serves as an
43 approximation of intestinal motility (10). Our group has shown that when *C. difficile* negative
44 samples from patients were separated into two groups based on stool consistency, there were
45 similar microbiota features between samples from CDI patients and *C. difficile* negative patients
46 with diarrhea compared to non-diarrheal samples that were *C. difficile* negative (12). The similar
47 community features between CDI patients and patients with diarrhea included low alpha diversity
48 and only 6 bacterial taxa with higher relative abundances in communities from CDI patients. These
49 results led to the hypothesis that bacterial communities from patients experiencing diarrhea are
50 susceptible to developing CDIs, regardless of how they developed diarrhea.

51 Depending on the dose administered, osmotic laxatives can lead to diarrhea and temporarily disrupt
52 the human intestinal microbiota (13). The ubiquitous osmotic laxative, polyethylene glycol (PEG)
53 3350 is found in Miralax, Nulytely, and Golytely and is also commonly used as bowel preparation
54 for colonoscopies. Interestingly, previous studies have shown that treating mice with PEG alone
55 altered microbiota composition, reduced acetate and butyrate production, altered the mucus barrier,
56 and rendered the mice susceptible to *C. difficile* colonization (14–17). The mucus barrier is thought
57 to mediate protection from CDIs by protecting intestinal epithelial cells from the toxins produced by
58 *C. difficile* (18, 19). Whether laxative administration results in more severe CDIs in mice and how
59 long mice remain colonized with *C. difficile* after challenge is unclear.

60 Beyond susceptibility, PEG is also relevant in the context of treating recurrent CDIs via fecal

61 microbiota transplant (FMT), where a healthy microbiota is administered to the patient to restore
62 colonization resistance. For FMTs that are delivered via colonoscopy, patients typically undergo
63 bowel preparation by taking an osmotic laxative prior to the procedure. Many of the FMT studies to
64 date rationalize the use of laxatives prior to the FMT (20–22) based on a 1996 case study with 2
65 pediatric patients where the authors suggested in the discussion that the laxative may help flush *C.*
66 *difficile* spores and toxins from the intestine (23).

67 Our group has used C57BL/6 mice to characterize how antibiotics disrupt the microbiota and
68 influence *C. difficile* susceptibility and clearance (24–26). Although two groups have now shown
69 that PEG treatment alone renders mice susceptible to *C. difficile* (15, 17), these studies have raised
70 additional questions regarding the dynamics and severity of infection as well as the role of laxative
71 treatment in *C. difficile* clearance. Here, we characterized how long PEG-treated mice remain
72 susceptible, whether PEG treatment results in more sustained *C. difficile* colonization and severe
73 CDI than mice treated with clindamycin, and whether PEG treatment after challenge can promote
74 *C. difficile* clearance. Addressing these questions will better inform how we think about laxatives
75 and diarrhea in the context of CDIs.

76 **Results**

77 **5-day laxative treatment led to prolonged *C. difficile* colonization in mice.** Building off of
78 previous work that showed treating mice with the osmotic laxative, PEG 3350, rendered mice
79 susceptible to *C. difficile* colonization (15, 17), we decided to test how long *C. difficile* colonization
80 is sustained and how long PEG-treated mice remain susceptible to *C. difficile*. We compared
81 three groups of mice treated with PEG 3350 to one group of mice treated with our standard 10
82 mg/kg clindamycin treatment, which temporarily renders mice susceptible to *C. difficile* colonization,
83 with mice typically clearing *C. difficile* within 10 days post-challenge (9, 26). All three groups of
84 PEG-treated mice were administered a 15% PEG solution in the drinking water for 5-days. The
85 first group received no additional treatment. The second group was also treated with clindamycin.
86 A third group was allowed to recover for 10 days prior to challenge (Fig. 1A). The PEG treatment
87 resulted in weight loss for the 3 groups of mice, with the greatest change in weight observed on
88 the fifth day of the PEG treatment. The mice recovered most of the lost weight by five days after

89 treatment (Fig. 1B). After either the PEG, clindamycin, or PEG and clindamycin treatment all mice
90 were challenged with 10^5 *C. difficile* 630 spores (Fig. 1A). All treatments rendered mice susceptible
91 to *C. difficile* colonization. In contrast to the mice that only received clindamycin, PEG-treated
92 mice remained colonized with *C. difficile* at a high level through thirty days post-challenge (Fig.
93 1C). The clindamycin-treated mice cleared *C. difficile* within ten days post-challenge (Fig. 1C).
94 It was noteworthy that PEG-treated mice were still susceptible to *C. difficile* colonization after a
95 10-day recovery period, although *C. difficile* was not detectable in most of the group in the initial
96 five days post-challenge (Fig. 1C, S1A). One mouse was found dead on the 6th day post-challenge,
97 presumably due to *C. difficile* as the bacterium became detectable in stool samples from that mouse
98 on the 4th day post-challenge (Fig. S1A, mouse 10). From 8 days post-challenge onward, the
99 density of *C. difficile* stabilized in the 10-day recovery group and remained high through 20-30
100 days post-challenge (Fig. 1C). Thus, osmotic laxative treatment alone was sufficient to render
101 mice susceptible to prolonged *C. difficile* colonization and PEG-treated mice remained susceptible
102 through ten days post-treatment.

103 **5-day laxative treatment differentially disrupted the fecal microbiota compared to**
104 **clindamycin treatment.** Since osmotic laxatives and clindamycin have previously been
105 shown to disrupt the murine microbiota (14–17), we hypothesized the different *C. difficile*
106 colonization dynamics between mice treated with the osmotic laxative or clindamycin were due to
107 the two drugs having differential effects on the microbiota. We profiled the stool microbiota over
108 time by sequencing the V4 region of the 16S rRNA gene to compare changes across treatment
109 groups. We found time ($R^2 = 0.29$) and treatment group ($R^2 = 0.21$) explained half of the observed
110 variation between fecal communities with most of the remaining variation explained by interactions
111 between treatment group and other experimental variables including time, cage, and sequencing
112 preparation plate (PERMANOVA combined $R^2 = 0.95$, $P < 0.001$, Fig. 2A, Data Set S1, sheet
113 1). None of the treatment groups recovered to their baseline community structure either 10 or 30
114 days post-challenge, suggesting other community features besides recovery to baseline were
115 responsible for the prolonged *C. difficile* colonization in PEG-treated mice (Fig. 2B).

116 Because time and treatment group influenced most of the variation between communities, we
117 next explored whether there were differences in community diversity and composition between

118 treatment groups. We examined the alpha diversity dynamics by calculating the communities'
119 Shannon diversity. Although both clindamycin and PEG treatments decreased diversity, the
120 Shannon diversity was lower in the groups of mice that received PEG treatment compared to those
121 that received clindamycin alone through thirty days post-challenge (Fig. 2C; Data Set S1, sheet 2).
122 We next identified the bacterial genera whose relative abundances shifted after PEG treatment by
123 comparing the baseline samples of mice treated with only PEG to samples from the same mice one
124 day post-PEG-treatment. We found 18 genera whose relative abundances were altered by PEG
125 treatment (Data Set S1, sheet 3). The majority of the bacterial relative abundances decreased after
126 the PEG treatment, but the relative abundance among members of the *Enterobacteriaceae* and
127 *Bacteroides* increased. The increase in *Bacteroides* relative abundance was unique to PEG treated
128 mice, as the *Bacteroides* relative abundance actually decreased in clindamycin treated mice (Fig.
129 2D). Finally, we identified the genera whose relative abundance differed across treatment groups
130 over multiple time points. Of the 33 genera that were different between treatment groups, 24 genera
131 were different over multiple time points (Fig. 2E, Data Set S1, sheet 4). Thus, PEG had a significant
132 impact on the fecal microbiota that was maintained over time and was distinct from clindamycin
133 treatment.

134 Because *C. difficile* was not immediately detectable in the stools of the PEG-treated mice that
135 were allowed to recover for 10 days prior to challenge, we decided to examine if there were
136 genera that changed during the post-challenge period. We compared the communities from when
137 *C. difficile* shifted from undetectable at 1 day post-challenge to detectable in the stool samples
138 with the density stabilizing around 8 days post-challenge (Fig. S1A). We found no genera with
139 relative abundances that were significantly different over the two time points (Data Set S1, sheet 5).
140 However, there was also wide variation between individual mice regarding when *C. difficile* became
141 detectable (Fig. S1A) as well as the relative abundances of bacterial genera in the communities
142 (Fig. S1B). For example, two mice had a high relative abundance of *Enterobacteriaceae* throughout
143 the post-challenge period. One mouse died on the sixth day post-challenge and in the other, *C.*
144 *difficile* was present at a high density from the 4th day post-challenge onward (Fig. S1B). While
145 we did not identify a clear signal to explain the delayed appearance of *C. difficile* in the 5-day PEG
146 mice that were allowed to recover for 10 days prior to challenge, the delay was striking and could

147 reflect changes in microbial activity or metabolites that were not examined in this study.

148 **5-day laxative treatment did not promote more severe CDIs despite altering the mucosal**
149 **microbiota.** Given the findings from a previous study that demonstrated PEG treatment disrupts
150 the mucus layer and alters the immune response in mice (16), we decided to examine the impact of
151 PEG treatment on the mucosal microbiota and CDI severity. To evaluate the mucosal microbiota,
152 we sequenced communities associated with tissues collected from the cecum, proximal colon, and
153 distal colon. Similar to what was observed with the stool samples, the alpha diversity was lower
154 in the PEG-treated mice compared to clindamycin treated mice (Fig. 3A, Data Set S1, sheet 6).
155 The alpha diversity of the tissue-associated community increased in PEG-treated mice collected
156 at 20 and 30 days post-challenge (Fig. 3A). Group ($R^2 = 0.33$), time point ($R^2 = 0.11$), and their
157 interactions with other variables (cage, experiment number, and sample type) explained the majority
158 of the variation observed in mucosal communities (PERMANOVA combined $R^2 = 0.83$, $P < 0.05$,
159 Fig. 3B, Data Set S1, sheet 7). We saw the greatest difference in the relative abundance of the
160 mucosal microbiota between treatment groups (clindamycin, 5-day PEG, and 5-day PEG plus
161 clindamycin) at 6 days post-challenge with 10 genera that were significantly different ($P < 0.05$) in
162 all three of the tissue types we collected (cecum, proximal colon, and distal colon; Fig. S2A, Data
163 Set S1, sheet 8, 9, and 10). Interestingly, *Peptostreptococcaceae* (the family with a sequence that
164 matches *C. difficile*) was one of the genera that had a significant difference in relative abundance
165 between treatment groups at 6 days post-challenge. This population was primarily only present
166 in the 5-day PEG treatment group of mice and decreased in the proximal and distal colon tissues
167 over time (Fig. S2B). By 30 days post-challenge, only the relative abundances of *Bacteroides*,
168 *Clostridiales*, *Firmicutes*, and *Ruminococcaceae* were different between treatment groups and
169 only in the cecum tissues (Fig. 3C, Fig. 2E, Data Set S1, sheet 8). Thus, PEG treatment had a
170 significant impact on the mucosal microbiota and we detected *C. difficile* sequences in the cecum,
171 proximal colon, and distal colon tissue communities.

172 Because there were differences in the mucosal microbiota, including detectable *C. difficile*
173 sequences in tissues from PEG-treated mice relative to mice treated with clindamycin, we next
174 examined the severity of *C. difficile* challenge by evaluating cecum and colon histopathology (27).
175 However, we found there was no difference in cecum and colon scores between clindamycin

176 and PEG-treated mice that were challenged with *C. difficile* at 4 days post-challenge (Fig. 3D),
177 the time point typically examined in *C. difficile* 630 challenged mice (28). We also looked at 6
178 days post-challenge because that was when there was a large difference in *C. difficile* density
179 between PEG- and clindamycin-treated mice (Fig. 1C). Although there was a slight difference in
180 the histopathology score of the colon between PEG and clindamycin-treated mice, there was not a
181 significant difference in the cecum and the overall score was relatively low (1.5 to 2.5 out of 12, Fig.
182 3E). Therefore, although PEG treatment had a disruptive effect on the mucosal microbiota, the
183 impact of *C. difficile* challenge on the cecum and colon was similar between PEG and clindamycin
184 treated mice.

185 ***C. difficile* challenge did not have a synergistic disruptive effect on the microbiota of**
186 **PEG-treated mice.** Because *C. difficile* itself can have an impact on the microbiota (29), we
187 also sequenced the tissue and stools of mock-challenged mice treated with clindamycin or PEG.
188 Examining the stools of the mock-challenged mice revealed similar bacterial disruptions as the *C.*
189 *difficile* challenged mice (Fig. S3A-C). Similarly, there was no difference between the communities
190 found in the tissues of mock and *C. difficile* challenged mice (Fig. S3D-F). Thus, most of the
191 microbiota alterations we observed in the PEG-treated mice were a result of the laxative and not an
192 interaction between the laxative and *C. difficile*.

193 **1-day laxative treatment resulted in transient *C. difficile* colonization and minor microbiota**
194 **disruption.** Next, we examined how a shorter osmotic laxative perturbation would impact the
195 microbiome and susceptibility to *C. difficile*. We administered either a 1-day PEG treatment, a
196 1-day PEG treatment with a 1-day recovery period, or clindamycin to mice before challenging them
197 with *C. difficile* (Fig. 3A). In contrast to the 5-day PEG treated mice, the 1-day PEG groups were
198 only transiently colonized and cleared *C. difficile* by 7 days post-challenge (Fig. 3B). The stool
199 communities of the 1-day PEG treatment groups were also only transiently disrupted, with Shannon
200 diversity recovering by 7 days post-challenge (Fig. 3C-D, Data Set S1, sheets 11 and 12). We found
201 the relative abundances of 14 genera were impacted by treatment, but recovered close to baseline
202 levels by 7 days post-challenge including *Enterobacteriaceae*, *Clostridiales*, *Porphyromonadaceae*,
203 and *Ruminococcaceae* (Fig. 3E, Data Set S1, sheet 13 and 14). These findings suggest the
204 duration of the PEG treatment was relevant, with shorter treatments resulting in a transient loss of

205 *C. difficile* colonization resistance.

206 **Post-challenge laxative treatment disrupted clearance in clindamycin-treated mice**
207 **regardless of whether an FMT was also administered.** Since a 1-day PEG treatment resulted
208 in a more mild perturbation of the microbiota, we decided to use the 1-day treatment to examine the
209 hypothesis that PEG helps to flush *C. difficile* spores from the intestine. This hypothesis is proposed
210 in the discussion section of FMT studies where bowel prep is part of the preparation undergone by
211 patients receiving FMTs via colonoscopy (20–23). To examine the impact of PEG treatment on
212 *C. difficile* clearance, we treated 4 groups of mice with clindamycin and then challenged all mice
213 with *C. difficile* before administering the following treatments: no additional treatment, 1-day PEG
214 immediately after challenge, and 1-day PEG treatment 3 days after challenge followed by either
215 administration of an FMT or PBS solution by oral gavage (Fig. 5A). Contrary to the hypothesis, all
216 groups of mice that received PEG exhibited prolonged *C. difficile* colonization (Fig. 5B).

217 We were also interested in exploring whether PEG might help with engraftment in the context of
218 FMTs. An FMT was prepared under anaerobic conditions using stool collected from the same
219 group of mice pre-treatment representing the baseline community. The FMT appeared to partially
220 restore Shannon diversity but not richness (Fig. 5C-D, Data Set S1, sheets 15 and 16). Similarly,
221 we saw some overlap between the communities of mice that received FMT and the mice treated
222 with only clindamycin after 5 days post-challenge (Fig. 6A, Data Set S1, sheet 17). The increase
223 in Shannon diversity suggests that the FMT did have an impact on the microbiota, despite seeing
224 prolonged *C. difficile* colonization in the FMT treated mice. However, only the relative abundances
225 of *Bacteroidales* and *Porphyromonadaceae* consistently differed between the mice that received
226 either an FMT or PBS gavage (Fig. 6B). Overall, we found the relative abundances of 24 genera
227 were different between treatment groups over multiple time points (Data Set S1, sheet 18). For
228 example, the relative abundance of *Akkermansia* was increased and the relative abundances of
229 *Ruminococcaceae*, *Clostridiales*, *Lachnospiraceae*, and *Oscillibacter* were decreased in mice that
230 received PEG after *C. difficile* challenge relative to clindamycin treated mice (Fig. 6C). In sum,
231 administering PEG actually prolonged *C. difficile* colonization, including in mice that received an
232 FMT, which only restored 2 bacterial genera.

233 **Five-day post-challenge community data can predict which mice will have prolonged**
234 **C. difficile colonization.** After identifying bacteria associated with the 5-day, 1-day and
235 post-challenge 1-day PEG treatments, we examined the bacteria that influenced prolonged C.
236 *difficile* colonization. We trained 3 machine learning models (random forest, logistic regression,
237 and support vector machine) with bacterial community data from 5 days post-challenge to predict
238 whether the mice were still colonized with *C. difficile* 10 days post-challenge. We chose to predict
239 the status based on communities 5 days post-challenge because that was the earliest time point
240 where we saw a treatment effect in the post-challenge 1-day PEG experiments. The random
241 forest model had the highest performance (median AUROC = 0.90, Data Set S1, sheet 19) and
242 indicated that the 5-day post challenge microbiota was an excellent predictor of prolonged *C.*
243 *difficile* colonization. Next, we performed a permutation importance test to identify the bacteria
244 that were the top contributors to the random forest model for predicting prolonged *C. difficile*
245 colonization. We selected 10 genera that contributed the most to our model's performance (Fig.
246 7A) and examined their relative abundance at 5 days post-challenge, the time point used to predict
247 *C. difficile* colonization status on day 10 (Fig. 7B). Next, we focused on the 5 genera that had a
248 greater than 1% relative abundance in either the cleared or colonized mice and examined how the
249 bacteria changed over time. We found *Enterobacteriaceae* and *Bacteroides* tended to consistently
250 have a higher relative abundance, the relative abundance of *Akkermansia* was initially low and then
251 increased, and *Porphyromonadaceae* and *Lachnospiraceae* had a lower relative abundance in the
252 mice with prolonged colonization compared to the mice that cleared *C. difficile* (Fig. 7C). Together
253 these results suggest a combination of low and high abundance bacterial genera influence the
254 prolonged colonization observed in 5-day PEG and post-challenge 1-day PEG treated mice.

255 **Discussion**

256 While the disruptive effect of antibiotics on *C. difficile* colonization resistance is well established,
257 the extent to which other drugs such as laxatives disrupt colonization resistance was unclear. By
258 following mice treated with an osmotic laxative over time, we found that a 5-day PEG treatment
259 before challenge resulted in prolonged *C. difficile* colonization, while a 1-day PEG treatment resulted
260 in transient colonization without the use of antibiotics. The differences in *C. difficile* colonization

261 dynamics between the 5- and 1-day PEG treated mice were associated with differences in the
262 degree to which treatments disrupted the microbiota. Additionally, the intestinal communities of
263 5-day PEG treated mice did not regain colonization resistance after a 10-day recovery period. In
264 contrast to the other 5-day PEG treatment groups, *C. difficile* was not immediately detectable in
265 the stools of most of the mice in the 10-day recovery group. We also examined the impact of PEG
266 treatment after *C. difficile* challenge. In opposition to the hypothesis suggested by the literature, we
267 found that PEG treatment prolonged colonization relative to mice that only received clindamycin
268 treatment. We identified patterns in the relative abundances of *Bacteroides*, *Enterobacteriaceae*,
269 *Akkermansia*, *Porphyromonadaceae*, and *Lachnospiraceae* that were associated with prolonged *C.*
270 *difficile* colonization (Fig. 8). Overall, our results demonstrated that osmotic laxative treatment alone
271 rendered mice susceptible to *C. difficile* colonization and the duration of colonization depended on
272 the length of PEG treatment and whether treatment was administered before or after challenge.

273 In addition to altering composition, laxative treatment may alter microbiota-produced metabolites. A
274 previous study demonstrated that a 5-day treatment of 10% PEG depleted acetate and butyrate
275 and increased succinate compared to untreated mice (15). While we did not perform metabolomic
276 analysis, we did see bacteria known to produce beneficial metabolites were depleted in mice
277 that cleared *C. difficile* compared to mice with prolonged colonization. For example, *Oscillibacter*
278 *valericigenes* can produce the SCFA valerate (30), and separate studies demonstrated valerate is
279 depleted after clindamycin treatment and inhibited *C. difficile* growth *in vitro* and in C57BL/6 mice
280 (31, 32). Similarly, *Acetatifactor* can produce acetate and butyrate (33), SCFAs that are decreased
281 in mice with prolonged *C. difficile* infection after antibiotic treatment (34). Thus protective bacteria
282 and their metabolites could be depleted by osmotive laxative treatment depending on the timing
283 and duration of treatment.

284 One possible explanation for the prolonged *C. difficile* colonization in 5-day PEG treated mice, might
285 be due to the bacteria's persistence in the mucosal compartment. In fact, it has been hypothesized
286 that *C. difficile* biofilms may serve as reservoirs for recurrent infections (35) and *C. difficile* biofilms
287 in the mucus layer were recently identified in patients as aggregates with *Fusobacterium nucleatum*
288 (36). There was an interesting pattern of increased *Enterobacteriaceae*, *Bacteroides*, and *C.*
289 *difficile* in both the stool and mucosal communities of PEG-treated mice suggesting a potential

290 synergy. *Bacteroides* has the potential to degrade mucus and the osmotic laxative may have allowed
291 *Bacteroides* to colonize the mucosal niche by degrading mucin glycans with glycosyl hydrolases
292 that are absent in *C. difficile* (37). *Bacteroides* persistence in the mucosal tissue might also have
293 helped *Enterobacteriaceae* to colonize the region, as a synergy between mucus-degrading *B.*
294 *fragilis* and *E. coli* has previously been described (38). A separate study demonstrated *C. difficile*
295 was present in the outer mucus layer and associated with *Enterobacteriaceae* and *Bacteroidaceae*
296 using fluorescent in situ hybridization (FISH) staining (39). However, protective roles for *Bacteroides*
297 have also been demonstrated. For example, *B. fragilis* prevented CDI morbidity in a mouse model
298 and inhibited *C. difficile* adherence *in vitro* (40). In coculture experiments, *B. longum* decreased
299 *C. difficile* biofilm formation while *B. thetaiotamicron* enhanced biofilm formation (41) and *B. dorei*
300 reduced *C. difficile* growth in a 9-species community *in vitro* (42). Therefore, whether *Bacteroides*
301 is detrimental or beneficial in the context of *C. difficile* infection or colonization is still unclear, but
302 the niche and interactions with other bacteria may contribute.

303 *Akkermansia* is also a mucin degrader with potentially beneficial or detrimental roles depending on
304 context in other diseases (43, 44). In our study, the relative abundance of *Akkermansia* shifted over
305 time between groups of mice that either cleared *C. difficile* or had prolonged colonization. In the stool
306 it was initially increased in mice that cleared *C. difficile*, but shifted after 5-days post-challenge so
307 that it was increased in mice that had prolonged colonization. In the context of CDIs, some studies
308 suggest a protective role (45, 46), while others suggest a detrimental role because *Akkermansia*
309 was positively correlated with *C. difficile* (47–50). Because the relative abundance of *Akkermansia*
310 was dynamic in our study, it is unclear whether *Akkermansia* helps with clearance of *C. difficile* or
311 allows it to persist. A better understanding how *C. difficile* interacts with the mucosal microbiota
312 may lead to insights into CDIs, asymptomatic *C. difficile* carriage, and colonization resistance.

313 Despite identifying an altered compositional profile that included higher relative abundance of
314 the *C. difficile* sequence in the mucosal tissues of mice treated with 5-day PEG compared to the
315 clindamycin group, we did not see a difference in histopathology scores between the groups. One
316 reason there was no difference could be the *C. difficile* strain used, *C. difficile* 630 results in mild
317 histopathology summary scores in mice compared to VPI 10463 despite both strains producing
318 toxin in mice (51). Part of our hypothesis for why there could have been increased histopathology

319 scores in PEG-treated mice was because PEG was previously shown to disrupt the mucus layer
320 in mice. However, recent studies demonstrated that broad spectrum antibiotics can also disrupt
321 the host mucosal barrier in mice (52, 53). Further research is needed to tease out the interplay
322 between medications that influence the mucus layer and different strains of *C. difficile* in the context
323 of CDIs.

324 It is more difficult to interpret what are findings mean in the context of *C. difficile* colonization
325 resistance in human patients. The main difficulty being that most hospitals recommend not
326 performing *C. difficile* testing if the patient is currently taking a laxative. This recommendation
327 is in accordance with the Infectious Diseases Society of America and Society for Healthcare
328 Epidemiology of America guidelines (54). The rationale behind the recommendation is that patients
329 taking laxatives may be asymptotically colonized with *C. difficile*, resulting in unnecessary
330 antibiotic treatment (55–57). Furthermore, some studies identified laxatives as a risk factor for
331 developing CDIs or recurrent CDIs (58–60) and a recent study found the proportion of severe CDIs
332 was similar between patients taking and not taking laxatives (61). However, there have also been
333 some studies that suggest laxatives are not a risk factor for developing CDIs (62, 63). Although, it
334 is unclear whether laxatives impact CDI susceptibility in human paitents, it is clear that laxatives
335 also have a transient impact on the human microbiota (13, 64–67). Additional studies to examine
336 the relationship between laxatives, *C. difficile* colonization, and CDIs are warranted.

337 Considering laxatives are also used to prepare patients when administering fecal microbiota
338 transplants via colonoscopy to treat recurrent CDIs, it will be important to determine whether
339 osmotic laxatives impact *C. difficile* clearance in the human intestinal tract. It is still unclear what
340 the best administration route is because there have been no studies designed to evaluate the best
341 administration route for FMTs (68). Nevertheless, results from the FMT National Registry where
342 85% of FMTs were delivered by colonoscopy demonstrate FMTs are highly effective treatment for
343 recurrent CDIs with 90% achieving resolution in the 1 month follow-up window (69). A surprising
344 number of studies continue to hypothesize that PEG or bowel preparation can clear *C. difficile*
345 spores and toxins despite the paucity of supporting evidence (20–23). There was even a clinical
346 trial (NCT01630096) designed to examine whether administering PEG 3350 (NuLYTELY) prior to
347 antibiotic treatment reduced disease severity that started recruitment in 2012 (70), but no results

348 have been posted to date. Here we sought to evaluate the impact of treating *C. difficile* colonized
349 mice with PEG (with or without FMT) and found clearance was delayed. Further studies are needed
350 to understand the impact of osmotic laxatives on *C. difficile* colonization resistance and clearance
351 in human patients receiving FMTs.

352 We have demonstrated that osmotic laxative treatment alone has a substantial impact on the
353 microbiota and rendered mice susceptible to prolonged *C. difficile* colonization in contrast to
354 clindamycin-treated mice. The duration and timing of the laxative treatment impacted the duration of
355 *C. difficile* colonization, with only 5-day PEG and post-challenge 1-day PEG treatments prolonging
356 colonization compared to clindamycin treated mice. Further studies are warranted to ascertain
357 whether laxatives have a similar impact on *C. difficile* colonization resistance on the human
358 microbiota.

359 Acknowledgements

360 We thank members of the Schloss lab for feedback on planning the experiments and data
361 presentation. We thank Andrew Henry for help with media preparation and bacterial culture and
362 the Microbiology and Immunology department's postdoctoral association writing group members
363 for their feedback on manuscript drafts. We also thank the Unit for Laboratory Animal Medicine at
364 the University of Michigan for maintaining our mouse colony and providing the institutional support
365 for our mouse experiments. Finally, we thank Kwi Kim, Austin Campbell, and Kimberly Vendrov
366 for their help in maintaining the Schloss lab's anaerobic chamber. This work was supported by
367 the National Institutes of Health (U01AI124255). ST was supported by the Michigan Institute for
368 Clinical and Health Research Postdoctoral Translation Scholars Program (UL1TR002240 from the
369 National Center for Advancing Translational Sciences).

370 Materials and Methods

371 **Animals.** All experiments were approved by the University of Michigan Animal Care and Use
372 Committee IACUC (protocol numbers PRO00006983 and PRO00008975). All mice were C57Bl/6
373 and part of the Schloss lab colony which was established in 2010 with mice donated from Vincent
374 Young's lab colony (established with mice purchased from The Jackson Laboratory in 2002). We

375 used 7-19 week old female mice for all experiments. This allowed us to break up littermates and
376 distribute them as evenly as possible across treatment groups in order to minimize microbiota
377 differences prior to starting treatments with medications. During the experiment, mice were housed
378 at a density of 2-3 mice per cage, with the majority of cages limited to two mice.

379 **Drug treatments.** For PEG treatment groups, fifteen percent PEG 3350 (Miralax) was administered
380 in the drinking water for either 5 or 1-day periods depending on the experiment. PEG solution
381 was prepared fresh every 2 days in distilled water and administered to the mice in water bottles.
382 Clindamycin treatment groups received distilled water in water bottles during the PEG-treatment
383 periods, with the water being changed at the same frequency. For clindamycin treatment, groups of
384 mice received 10 mg/kg clindamycin (Sigma-Aldrich) via intraperitoneal injection. All PEG treatment
385 groups received a sham intraperitoneal injection containing filter sterilized saline.

386 **C. difficile challenge model.** Mice were challenged with 25 microliters containing 10^5 *C. difficile*
387 630 spores, except for 1 experiment where the concentration was 10^3 (Fig. 5A). All mock challenged
388 mice received 25 ul vehicle solution (Ultrapure water). A Dymax stepper pipette was used to
389 administer the same challenge dose to mice via oral gavage. Mice were weighed daily throughout
390 the experiment and stool was collected for quantifying *C. difficile* CFU and 16S rRNA gene
391 sequencing. There were two groups of mice that received either a PBS or fecal microbiota
392 transplant (FMT) gavage post-PEG treatment. The fecal microbiota transplant was prepared with
393 stool samples collected from the mice in the experiment prior to the start of any treatments. The
394 stool samples were transferred to an anaerobic chamber and diluted 1:10 in reduced PBS and
395 glycerol was added to make a 15% glycerol solution. The solution was then aliquoted into tubes and
396 stored at -80 °C until the day of the gavage. An aliquot of both the FMT and PBS solutions were also
397 set aside in the -80 °C for 16S rRNA gene sequencing. The day of the gavage, aliquots were thawed
398 and centrifuged at 7500 RPM for 1 minute. The supernatant was then transferred to a separate
399 tube to prevent the gavage needle from clogging with debris during gavage. The PBS solution that
400 was administered to the other group was also 15% glycerol. Each mouse was administered 100
401 microliters of either the FMT or PBS solution via gavage. When we refer to mice that cleared *C.*
402 *difficile*, we mean that no *C. difficile* was detected in the first serial dilution (limit of detection: 100
403 CFU). In some experiments, we collected tissues for 16SrRNA gene sequencing, histopathology,

404 or both. For 16S rRNA gene sequencing, we collected small snips of cecum, proximal colon, and
405 distal colon tissues in microcentrifuge tubes, snap froze in liquid nitrogen, and stored at -80 °C.
406 For histopathology, cecum and colon tissues were placed into separate cassettes, fixed, and
407 then submitted to McClinchey Histology Labs (Stockbridge, MI) for processing, embedding, and
408 hematoxylin and eosin (H&E) staining.

409 **C. difficile quantification.** Stool samples from mice were transferred to an anaerobic chamber and
410 serially diluted in reduced PBS. Serial dilutions were plated onto taurocholate-cycloserine-cefoxitin-fructose
411 agar (TCCFA) plates and counted after 24 hours of incubation at 37 °C. Stool samples
412 collected from the mice on day 0 post-challenge were also plated onto TCCFA plates to ensure
413 mice were not already colonized with *C. difficile* prior to challenge.

414 **16S rRNA gene sequencing.** Stool samples were stored at -80 °C and were placed into 96-well
415 plates for DNA extractions and library preparation. DNA was extracted using the DNeasy Powersoil
416 HTP 96 kit (Qiagen) and an EpMotion 5075 automated pipetting system (Eppendorf). For library
417 preparation, each plate had a mock community control (ZymoBIOMICS microbial community DNA
418 standards) and a negative control (water). The V4 region of the 16S rRNA gene was amplified with
419 the AccuPrime Pfx DNA polymerase (Thermo Fisher Scientific) using custom barcoded primers, as
420 previously described (71). The PCR amplicons were normalized (SequalPrep normalizatin plate kit
421 from Thermo Fisher Scientific), pooled and quantified (KAPA library quantification kit from KAPA
422 Biosystems), and sequenced with the MiSeq system (Illumina).

423 **16S rRNA gene sequence analysis.** All sequences were processed with mothur (v. 1.43) using
424 a previously published protocol (71, 72). Paired sequencing reads were combined and aligned
425 with the SILVA (v. 132) reference database (73) and taxonomy was assigned with a modified
426 version of the Ribosomal Database Project reference sequences (v. 16) (74). The error rate for
427 sequencing data was 0.0559% based on the 17 mock communities we ran with the samples.
428 Samples were rarefied to 1,000 sequences, 1,000 times for alpha and beta diversity analyses
429 in order to account for uneven sequencing across samples. All but 3 of the 17 water controls
430 had fewer than 1000 sequences. PCoAs were generated based on Bray-Curtis Index distance
431 matrices. Permutational multivariate analysis of variance (PERMANOVA) tests were performed on

432 mothur-generated Bray-Curtis distance matrices with the adonis function from the vegan R package
433 (75).

434 **Histopathology.** H&E stained sections of cecum and colon tissues collected at either 0, 4, or 6
435 days post-challenge were coded to be scored in a blinded manner by a board-certified veterinary
436 pathologist (ILB). Slides were evaluated using a scoring system developed for mouse models of *C.*
437 *difficile* infection (51). Each slide was evaluated for edema, cellular infiltration, and inflammation
438 and given a score ranging from 0-4. The summary score was calculated by combining the scores
439 from the 3 categories and ranged from 0-12.

440 **Classification model training and evaluation.** We used the mikropml package to train and
441 evaluate models to predict *C. difficile* colonization status 10 days post-challenge where mice were
442 categorized as either cleared or colonized (76, 77). We removed the *C. difficile* genus relative
443 abundance data prior to training the model. Input community relative abundance data at the
444 genus level from 5 days post-challenge was used to generate random forest, logistic regression,
445 and support vector machine classification models to predict *C. difficile* colonization status 10 days
446 post-challenge. To accommodate the small number of samples in our data set we used 50% training
447 and 50% testing splits with repeated 2-fold cross-validation of the training data for hyperparameter
448 tuning. Permutation importance was performed as described previously (78) using mikropml (76,
449 77) with the random forest model because it had the highest AUROC value.

450 **Statistical analysis.** R (v. 4.0.2) and the tidyverse package (v. 1.3.0) were used for statistical
451 analysis (79, 80). Kruskal-Wallis tests with Benjamini-Hochberg correction for testing multiple time
452 points were used to analyze differences in *C. difficile* CFU, mouse weight change, and alpha
453 diversity between treatment groups. Paired Wilcoxon rank signed rank tests were used to identify
454 genera impacted by treatments on matched pairs of samples from 2 time points. Bacterial relative
455 abundances that varied between treatment groups at the genus level were identified with the
456 Kruskal-Wallis test with Benjamini-Hochberg correction for testing all identified OTUs, followed by
457 pairwise Wilcoxon comparisons with Benjamini-Hochberg correction.

458 **Code availability.** Code for data analysis and generating this paper with accompanying figures is
459 available at https://github.com/SchlossLab/Tomkovich_PEG3350_mSphere_2021.

⁴⁶⁰ **Data availability.** The 16S rRNA sequencing data have been deposited in the National Center for
⁴⁶¹ Biotechnology Information Sequence Read Archive (BioProject Accession no. PRJNA727293).

462 **References**

- 463 1. Britton RA, Young VB. 2014. Role of the intestinal microbiota in resistance to colonization by
464 *Clostridium difficile*. *Gastroenterology* 146:1547–1553.
- 465 2. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez
466 KC, Dose H, Mori H, Patil KR, Bork P, Typas A. 2018. Extensive impact of non-antibiotic drugs on
467 human gut bacteria. *Nature* 555:623–628.
- 468 3. Bastard QL, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D,
469 Montassier E. 2017. Systematic review: Human gut dysbiosis induced by non-antibiotic prescription
470 medications. *Alimentary Pharmacology & Therapeutics* 47:332–345.
- 471 4. Vila AV, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE,
472 Mascllee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK. 2020. Impact of
473 commonly used drugs on the composition and metabolic function of the gut microbiota. *Nature*
474 *Communications* 11.
- 475 5. Oh J, Makar M, Fusco C, McCaffrey R, Rao K, Ryan EE, Washer L, West LR, Young VB, Guttag J,
476 Hooper DC, Shenoy ES, Wiens J. 2018. A generalizable, data-driven approach to predict daily risk
477 of *Clostridium difficile* infection at two large academic health centers. *Infection Control & Hospital*
478 *Epidemiology* 39:425–433.
- 479 6. Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, DuPont HL, Garey KW. 2012. Moderate
480 to high use of opioid analgesics are associated with an increased risk of *Clostridium difficile* infection.
481 *The American Journal of the Medical Sciences* 343:277–280.
- 482 7. Nehra AK, Alexander JA, Loftus CG, Nehra V. 2018. Proton pump inhibitors: Review of emerging
483 concerns. *Mayo Clinic Proceedings* 93:240–246.
- 484 8. Krishna SG, Zhao W, Apewokin SK, Krishna K, Chepyala P, Anaissie EJ. 2013. Risk factors,
485 preemptive therapy, and antiperistaltic agents for *Clostridium difficile* infection in cancer patients.
486 *Transplant Infectious Disease* n/a–n/a.

- 487 9. Tomkovich S, Lesniak NA, Li Y, Bishop L, Fitzgerald MJ, Schloss PD. 2019. The proton
488 pump inhibitor omeprazole does not promote *Clostridioides difficile* colonization in a murine model.
489 mSphere 4.
- 490 10. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. 2015. Stool consistency
491 is strongly associated with gut microbiota richness and composition, enterotypes and bacterial
492 growth rates. Gut 65:57–62.
- 493 11. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. 2020. Host variables
494 confound gut microbiota studies of human disease. Nature 587:448–454.
- 495 12. Schubert AM, Rogers MAM, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM,
496 Schloss PD. 2014. Microbiome data distinguish patients with *Clostridium difficile* infection and
497 non-*C. difficile*-associated diarrhea from healthy controls. mBio 5.
- 498 13. Nagata N, Tohya M, Fukuda S, Suda W, Nishijima S, Takeuchi F, Ohsugi M, Tsujimoto T,
499 Nakamura T, Shimomura A, Yanagisawa N, Hisada Y, Watanabe K, Imbe K, Akiyama J, Mizokami
500 M, Miyoshi-Akiyama T, Uemura N, Hattori M. 2019. Effects of bowel preparation on the human gut
501 microbiome and metabolome. Scientific Reports 9.
- 502 14. Kashyap PC, Marcabal A, Ursell LK, Larauche M, Duboc H, Earle KA, Sonnenburg ED, Ferreyra
503 JA, Higginbottom SK, Million M, Tache Y, Pasricha PJ, Knight R, Farrugia G, Sonnenburg JL. 2013.
504 Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice.
505 Gastroenterology 144:967–977.
- 506 15. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. 2014. Gut
507 microbiota-produced succinate promotes *C. difficile* infection after antibiotic treatment or motility
508 disturbance. Cell Host & Microbe 16:770–777.
- 509 16. Tropini C, Moss EL, Merrill BD, Ng KM, Higginbottom SK, Casavant EP, Gonzalez CG, Fremin B,
510 Bouley DM, Elias JE, Bhatt AS, Huang KC, Sonnenburg JL. 2018. Transient osmotic perturbation
511 causes long-term alteration to the gut microbiota. Cell 173:1742–1754.e17.
- 512 17. VanInsberghe D, Elsherbini JA, Varian B, Poutahidis T, Erdman S, Polz MF. 2020. Diarrhoeal

- 513 events can trigger long-term *Clostridium difficile* colonization with recurrent blooms. Nature
514 Microbiology 5:642–650.
- 515 18. Olson A, Diebel LN, Liberati DM. 2013. Effect of host defenses on *Clostridium difficile*
516 toxininduced intestinal barrier injury. Journal of Trauma and Acute Care Surgery 74:983–990.
- 517 19. Diebel LN, Liberati DM. 2014. Reinforcement of the intestinal mucus layer protects against
518 *Clostridium difficile* intestinal injury in vitro. Journal of the American College of Surgeons
519 219:460–468.
- 520 20. Nood E van, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, Vos WM de, Visser CE, Kuijper
521 EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. 2013. Duodenal infusion
522 of donor feces for recurrent *Clostridium difficile*. New England Journal of Medicine 368:407–415.
- 523 21. Razik R, Osman M, Lieberman A, Allegretti JR, Kassam Z. 2017. Faecal microbiota
524 transplantation for *Clostridium difficile* infection: A multicentre study of non-responders. Medical
525 Journal of Australia 207:159–160.
- 526 22. Postigo R, Kim JH. 2012. Colonoscopic versus nasogastric fecal transplantation for the
527 treatment of *Clostridium difficile* infection: A review and pooled analysis. Infection 40:643–648.
- 528 23. Liacouras CA, Piccoli DA. 1996. Whole-bowel irrigation as an adjunct to the treatment of
529 chronic, relapsing *Clostridium difficile* colitis. Journal of Clinical Gastroenterology 22:186–189.
- 530 24. Schubert AM, Sinani H, Schloss PD. 2015. Antibiotic-induced alterations of the murine gut
531 microbiota and subsequent effects on colonization resistance against *Clostridium difficile*. mBio 6.
- 532 25. Jenior ML, Leslie JL, Young VB, Schloss PD. 2017. *Clostridium difficile* colonizes alternative
533 nutrient niches during infection across distinct murine gut microbiomes. mSystems 2.
- 534 26. Tomkovich S, Stough JMA, Bishop L, Schloss PD. 2020. The initial gut microbiota and response
535 to antibiotic perturbation influence *Clostridioides difficile* clearance in mice. mSphere 5.
- 536 27. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay
537 between microbiome dynamics and pathogen dynamics in a murine model of *Clostridium difficile*

- 538 infection 2:145–158.
- 539 28. Dieterle MG, Putler R, Perry DA, Menon A, Abernathy-Close L, Perlman NS, Penkevich A,
540 Standke A, Keidan M, Vendrov KC, Bergin IL, Young VB, Rao K. 2020. Systemic inflammatory
541 mediators are effective biomarkers for predicting adverse outcomes in *Clostridioides difficile*
542 infection. mBio 11.
- 543 29. Jenior ML, Leslie JL, Young VB, Schloss PD. 2018. *Clostridium difficile* alters the structure and
544 metabolism of distinct cecal microbiomes during initial infection to promote sustained colonization.
545 mSphere 3.
- 546 30. Iino T, Mori K, Tanaka K, Suzuki K-i, Harayama S. 2007. *Oscillibacter valericigenes* gen. Nov.,
547 sp. Nov., a valerate-producing anaerobic bacterium isolated from the alimentary canal of a japanese
548 corbicula clam. International Journal of Systematic and Evolutionary Microbiology 57:1840–1845.
- 549 31. Jump RLP, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, Nerandzic
550 MM, Donskey CJ. 2014. Metabolomics analysis identifies intestinal microbiota-derived biomarkers
551 of colonization resistance in clindamycin-treated mice. PLoS ONE 9:e101267.
- 552 32. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, Holmes E, Li JV, Clarke
553 TB, Thursz MR, Marchesi JR. 2018. Inhibiting growth of *Clostridioides difficile* by restoring valerate,
554 produced by the intestinal microbiota. Gastroenterology 155:1495–1507.e15.
- 555 33. Pfeiffer N, Desmarchelier C, Blaut M, Daniel H, Haller D, Clavel T. 2012. *Acetatifactor muris*
556 gen. Nov., sp. Nov., a novel bacterium isolated from the intestine of an obese mouse. Archives of
557 Microbiology 194:901–907.
- 558 34. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R,
559 Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan
560 G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy
561 resolves relapsing *Clostridium difficile* disease in mice. PLoS Pathogens 8:e1002995.
- 562 35. Frost LR, Cheng JKJ, Unnikrishnan M. 2021. *Clostridioides difficile* biofilms: A mechanism of
563 persistence in the gut? PLOS Pathogens 17:e1009348.

- 564 36. Engevik MA, Danhof HA, Auchtung J, Endres BT, Ruan W, Bassères E, Engevik AC, Wu Q,
565 Nicholson M, Luna RA, Garey KW, Crawford SE, Estes MK, Lux R, Yacyshyn MB, Yacyshyn B,
566 Savidge T, Britton RA, Versalovic J. 2021. *Fusobacterium nucleatum* adheres to *Clostridioides*
567 *difficile* via the RadD adhesin to enhance biofilm formation in intestinal mucus. *Gastroenterology*
568 160:1301–1314.e8.
- 569 37. Engevik MA, Engevik AC, Engevik KA, Auchtung JM, Chang-Graham AL, Ruan W, Luna RA,
570 Hyser JM, Spinler JK, Versalovic J. 2020. Mucin-degrading microbes release monosaccharides
571 that chemoattract *Clostridioides difficile* and facilitate colonization of the human intestinal mucus
572 layer. *ACS Infectious Diseases* 7:1126–1142.
- 573 38. Dejea CM, Fathi P, Craig JM, Boleijj A, Taddese R, Geis AL, Wu X, Shields CED, Hechenbleikner
574 EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F,
575 Sears CL. 2018. Patients with familial adenomatous polyposis harbor colonic biofilms containing
576 tumorigenic bacteria. *Science* 359:592–597.
- 577 39. Semenyuk EG, Poroyko VA, Johnston PF, Jones SE, Knight KL, Gerding DN, Driks A. 2015.
578 Analysis of bacterial communities during *Clostridium difficile* infection in the mouse. *Infection and*
579 *Immunity* 83:4383–4391.
- 580 40. Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, Wang Y, Bai Y, Fan H, Zhao X, Zhi F. 2018.
581 *Bacteroides fragilis* prevents *Clostridium difficile* infection in a mouse model by restoring gut barrier
582 and microbiome regulation. *Frontiers in Microbiology* 9.
- 583 41. Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis
584 G, Henn MR, Ford CB, Wilcox MH, Buckley AM. 2021. Biofilms harbour *Clostridioides difficile*,
585 serving as a reservoir for recurrent infection. *npj Biofilms and Microbiomes* 7.
- 586 42. Hassall J, Cheng JKJ, Unnikrishnan M. 2021. Dissecting individual interactions between
587 pathogenic and commensal bacteria within a multispecies gut microbial community. *mSphere* 6.
- 588 43. Cirstea M, Radisavljevic N, Finlay BB. 2018. Good bug, bad bug: Breaking through microbial
589 stereotypes. *Cell Host & Microbe* 23:10–13.

- 590 44. Canha MB. 2015. Role of colonic microbiota in colorectal carcinogenesis: A systematic review.
591 Revista Española de Enfermedades Digestivas 107.
- 592 45. Pereira FC, Wasmund K, Cobankovic I, Jehmlich N, Herbold CW, Lee KS, Sziranyi B, Vesely
593 C, Decker T, Stocker R, Warth B, Bergen M von, Wagner M, Berry D. 2020. Rational design of a
594 microbial consortium of mucosal sugar utilizers reduces *Clostridioides difficile* colonization. Nature
595 Communications 11.
- 596 46. Rodriguez C, Taminiau B, Korsak N, Avesani V, Broeck JV, Brach P, Delmée M, Daube G. 2016.
597 Longitudinal survey of *Clostridium difficile* presence and gut microbiota composition in a belgian
598 nursing home. BMC Microbiology 16.
- 599 47. Sangster W, Hegarty JP, Schieffer KM, Wright JR, Hackman J, Toole DR, Lamendella R, Stewart
600 DB. 2016. Bacterial and fungal microbiota changes distinguish *C. difficile* infection from other forms
601 of diarrhea: Results of a prospective inpatient study. Frontiers in Microbiology 7.
- 602 48. Vakili B, Fateh A, Aghdaei HA, Sotoodehnejadnematalahi F, Siadat SD. 2020. Intestinal
603 microbiota in elderly inpatients with *Clostridioides difficile* infection. Infection and Drug Resistance
604 Volume 13:2723–2731.
- 605 49. Vakili B, Fateh A, Aghdaei HA, Sotoodehnejadnematalahi F, Siadat SD. 2020. Characterization
606 of gut microbiota in hospitalized patients with *Clostridioides difficile* infection. Current Microbiology
607 77:1673–1680.
- 608 50. Li X, Chu Q, Huang Y, Xiao Y, Song L, Zhu S, Kang Y, Lu S, Xu J, Ren Z. 2019. Consortium of
609 probiotics attenuates colonization of *Clostridioides difficile*. Frontiers in Microbiology 10.
- 610 51. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011.
611 Cefoperazone-treated mice as an experimental platform to assess differential virulence of
612 *Clostridium difficile* strains. Gut Microbes 2:326–334.
- 613 52. Kester JC, Brubaker DK, Velazquez J, Wright C, Lauffenburger DA, Griffith LG. 2020.
614 *Clostridioides difficile*-associated antibiotics alter human mucosal barrier functions by
615 microbiome-independent mechanisms. Antimicrobial Agents and Chemotherapy 64.


- 616 53. Bergstrom K, Shan X, Casero D, Batushansky A, Lagishetty V, Jacobs JP, Hoover C, Kondo
617 Y, Shao B, Gao L, Zandberg W, Noyovitz B, McDaniel JM, Gibson DL, Pakpour S, Kazemian N,
618 McGee S, Houchen CW, Rao CV, Griffin TM, Sonnenburg JL, McEver RP, Braun J, Xia L. 2020.
619 Proximal colon-derived o-glycosylated mucus encapsulates and modulates the microbiota. *Science*
620 370:467–472.
- 621 54. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey
622 KW, Gould CV, Kelly C, Loo V, Sammons JS, Sandora TJ, Wilcox MH. 2018. Clinical practice
623 guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the infectious
624 diseases society of america (IDSA) and society for healthcare epidemiology of america (SHEA).
625 *Clinical Infectious Diseases* 66:e1–e48.
- 626 55. Ahmad SM, Blanco N, Dewart CM, Dobosz A, Malani AN. 2017. Laxative use in the setting
627 of positive testing for *Clostridium difficile* infection. *Infection Control & Hospital Epidemiology*
628 38:1513–1515.
- 629 56. Bilinskaya A, Goodlet KJ, Nailor MD. 2018. Evaluation of a best practice alert to reduce
630 unnecessary *Clostridium difficile* testing following receipt of a laxative. *Diagnostic Microbiology and*
631 *Infectious Disease* 92:50–55.
- 632 57. Cook PP, Nichols S, Coogan M, Opera J, DeHart M. 2020. Reduction in testing and change in
633 testing algorithm associated with decrease in number of nosocomial *Clostridioides* (*Clostridium*)
634 *difficile* infections. *American Journal of Infection Control* 48:1019–1022.
- 635 58. Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. 2019. Predictors of
636 *Clostridioides difficile* recurrence across a national cohort of veterans in outpatient, acute, and
637 long-term care settings. *American Journal of Health-System Pharmacy* 76:581–590.
- 638 59. Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. 2011. Development
639 and validation of a *Clostridium difficile* infection risk prediction model. *Infection Control & Hospital*
640 *Epidemiology* 32:360–366.
- 641 60. Obritsch MD, Stroup JS, Carnahan RM, Scheck DN. 2010. *Clostridium difficile*-associated

- 642 diarrhea in a tertiary care medical center. Baylor University Medical Center Proceedings
643 23:363–367.
- 644 61. White NC, Mendo-Lopez R, Papamichael K, Cuddemi CA, Barrett C, Daugherty K, Pollock N,
645 Kelly CP, Alonso CD. 2019. Laxative use does not preclude diagnosis or reduce disease severity in
646 *Clostridioides difficile* infection. Clinical Infectious Diseases 71:1472–1478.
- 647 62. Poirier D, Gervais P, Fuchs M, Roussy J-F, Paquet-Bolduc B, Trottier S, Longtin J, Loo VG,
648 Longtin Y. 2019. Predictors of *Clostridioides difficile* infection among asymptomatic, colonized
649 patients: A retrospective cohort study. Clinical Infectious Diseases 70:2103–2210.
- 650 63. Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, Nord CE. 2014. Risk factors of *Clostridium*
651 *difficile* infections among patients in a university hospital in shanghai, china. Anaerobe 30:65–69.
- 652 64. Gorkiewicz G, Thallinger GG, Trajanoski S, Lackner S, Stocker G, Hinterleitner T, Güly C,
653 Högenauer C. 2013. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS
654 ONE 8:e55817.
- 655 65. Shobar RM, Velineni S, Keshavarzian A, Swanson G, DeMeo MT, Melson JE, Losurdo J, Engen
656 PA, Sun Y, Koenig L, Mutlu EA. 2016. The effects of bowel preparation on microbiota-related metrics
657 differ in health and in inflammatory bowel disease and for the mucosal and luminal microbiota
658 compartments. Clinical and Translational Gastroenterology 7:e143.
- 659 66. Drago L, Toscano M, Grandi RD, Casini V, Pace F. 2016. Persisting changes of intestinal
660 microbiota after bowel lavage and colonoscopy. European Journal of Gastroenterology &
661 Hepatology 28:532–537.
- 662 67. Jalanka J, Salonen A, Salojärvi J, Ritari J, Immonen O, Marciani L, Gowland P, Hoad C, Garsed
663 K, Lam C, Palva A, Spiller RC, Vos WM de. 2014. Effects of bowel cleansing on the intestinal
664 microbiota. Gut 64:1562–1568.
- 665 68. Kampouri E, Croxatto A, Prod'hom G, Guery B. 2021. *Clostridioides difficile* infection, still a
666 long way to go. Journal of Clinical Medicine 10:389.


- 667 69. Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM,
668 Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah
669 I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu
670 RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. 2021. Fecal microbiota
671 transplantation is highly effective in real-world practice: Initial results from the FMT national registry.
672 Gastroenterology 160:183–192.e3.
- 673 70. Dieterle MG, Rao K, Young VB. 2018. Novel therapies and preventative strategies for primary
674 and recurrent *Clostridium difficile* infections. Annals of the New York Academy of Sciences
675 1435:110–138.
- 676 71. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a
677 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the
678 MiSeq illumina sequencing platform. Applied and Environmental Microbiology 79:5112–5120.
- 679 72. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA,
680 Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber CF.
681 2009. Introducing mothur: Open-source, platform-independent, community-supported software
682 for describing and comparing microbial communities. Applied and Environmental Microbiology
683 75:7537–7541.
- 684 73. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2012.
685 The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools.
686 Nucleic Acids Research 41:D590–D596.
- 687 74. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-Alfaro A, Kuske CR,
688 Tiedje JM. 2013. Ribosomal database project: Data and tools for high throughput rRNA analysis.
689 Nucleic Acids Research 42:D633–D642.
- 690 75. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, Minchin PR, O'Hara RB,
691 Simpson GL, Solymos P, Stevens MHH, Szoecs E, Wagner H. 2018. Vegan: Community ecology
692 package.

- 693 76. Topçuoğlu B, Lapp Z, Sovacool KL, Snitkin E, Wiens J, Schloss PD. 2020. mikRopML:
694 User-friendly r package for robust machine learning pipelines.
- 695 77. Topçuoğlu B, Lapp Z, Sovacool K, Snitkin E, Wiens J, Schloss P. 2021. Mikropml: User-friendly
696 r package for supervised machine learning pipelines. Journal of Open Source Software 6:3073.
- 697 78. Topçuoğlu BD, Lesniak NA, Ruffin MT, Wiens J, Schloss PD. 2020. A framework for effective
698 application of machine learning to microbiome-based classification problems. mBio 11.
- 699 79. R Core Team. 2020. R: A language and environment for statistical computing. R Foundation for
700 Statistical Computing, Vienna, Austria.
- 701 80. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes
702 A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D,
703 Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the
704 tidyverse. Journal of Open Source Software 4:1686.


A



B




C



705

706 **Figure 1. 5-day PEG treatment prolongs susceptibility and mice become persistently**
707 **colonized with *C. difficile*.** A. Setup of the experimental time line for experiments with 5-day PEG
708 treated mice consisting of 4 treatment groups. 1. Clindamycin was administered at 10 mg/kg by


709 intraperitoneal injection. 2. 15% PEG 3350 was administered in the drinking water for five days. 3.
710 5-day PEG plus clindamycin treatment. 4. 5-day PEG plus 10-day recovery treatment. All treatment
711 groups were then challenged with 10^5 *C. difficile* 630 spores. A subset of mice were euthanized
712 on either 4 or 6 days post-challenge and tissues were collected for histopathology analysis, the
713 remaining mice were followed through 20 or 30 days post-challenge. B. Weight change from
714 baseline weight in groups after treatment with PEG and/or clindamycin, followed by *C. difficile*
715 challenge. C. *C. difficile* CFU/gram stool measured over time via serial dilutions(N = 10-59 mice
716 per time point). The black line represents the limit of detection for the first serial dilution. CFU
717 quantification data was not available for each mouse due to stool sampling difficulties (particularly
718 the day the mice came off of the PEG treatment) or early deaths. For B-C, lines represent the
719 median for each treatment group and circles represent samples from individual mice. Asterisks
720 indicate time points where the weight change or CFU/g was significantly different ($P < 0.05$)
721 between groups by the Kruskal-Wallis test with Benjamini-Hochberg correction for testing multiple
722 time points. The data presented are from a total of 5 separate experiments.



723

Figure 2. 5-day PEG treatment disrupts the stool microbiota for a longer amount of time


725 **compared to clindamycin-treated mice.** A. Principal Coordinate analysis (PCoA) of Bray-Curtis
726 distances from stool samples collected throughout the experiment. Each circle represents a
727 sample from an individual mouse and the transparency of the symbol corresponds to the day
728 post-challenge. See Data Set S1, sheet 1 for PERMANOVA results. B. Bray-Curtis distances of
729 stool samples collected on either day 10 or 30 post-challenge relative to the baseline sample
730 collected for each mouse (before any drug treatments were administered). The symbols represent
731 samples from individual mice and the line indicates the median value for each treatment group.
732 C. Shannon diversity in stool communities over time. The line indicates the median value for
733 each treatment group (Data Set S1, sheet 2). D. 14 of the 33 genera affected by PEG treatment
734 (Data Set S1, sheet 3). The symbols represent the median relative abundance for a treatment
735 group at either baseline (open circle) or 1-day post treatment (closed circle). Relative abundance
736 data from paired baseline and 1-day post treatment stool samples from the 5-day PEG and
737 5-day PEG plus 10-day recovery groups were analyzed by paired Wilcoxon signed-rank test with
738 Benjamini-Hochberg correction for testing all identified genera. The clindamycin and 5-day PEG
739 plus clindamycin treatment groups are shown on the plot for comparison. E. 6 of the 24 genera
740 that were significantly different between the treatment groups over multiple time points (see Data
741 Set S1, sheet 4 for complete list). The 5-day PEG plus clindamycin treatment group was only
742 followed through 6-days post-challenge. Differences between treatment groups were identified by
743 Kruskal-Wallis test with Benjamini-Hochberg correction for testing all identified genera (*, $P < 0.05$).
744 The gray vertical line (D) and horizontal vertical lines (E) indicate the limit of detection.



745

Figure 3. 5-day PEG treatment does not result in more severe CDIs, although mucosal

747 **microbiota is altered.** A. Shannon diversity in cecum communities over time. The colors of the
748 symbols and lines represent individual and median relative abundance values for four treatment
749 groups (Data Set S1, sheet 6). B. PCoA of Bray-Curtis distances from mucosal samples collected
750 throughout the experiment. Circles, triangles, and squares indicate the cecum, proximal colon,
751 and distal colon communities, respectively. Transparency of the symbol corresponds to the day
752 post-challenge that the sample was collected. See Data Set S1, sheet 7 for PERMANOVA results.
753 C. The median relative abundance of the 4 genera that were significantly different between the
754 cecum communities of different treatment groups on day 6 and day 30 post-challenge (Data Set S1,
755 sheet 8). The gray vertical lines indicate the limit of detection. D-E. The histopathology summary
756 scores from cecum and colon H&E stained tissue sections. The summary score is the total score
757 based on evaluation of edema, cellular infiltration, and inflammation in either the cecum or colon
758 tissue. Each category is given a score ranging from 0-4, thus the maximum possible summary
759 score is 12. The tissue for histology was collected at either 4 (D) or 6 (E) days post-challenge
760 with the exception that one set of 5-day PEG treated mock-challenged mice were collected on
761 day 0 post-challenge (first set of open purple circles in D). Histology data were analyzed with the
762 Kruskal-Wallis test followed by pairwise Wilcoxon comparisons with Benjamini-Hochberg correction.
763 *, $P < 0.05$.



764

765 **Figure 4. 1-day PEG treatment renders mice susceptible to transient *C. difficile* colonization.** A. Setup of the experimental time line for the 1-day PEG treated mice
 766 consisting of 3 treatment groups. 1. Clindamycin was administered at 10 mg/kg by intraperitoneal
 767 injection. 2. 15% PEG 3350 was administered in the drinking water for 1 day. 3. 1-day PEG
 768 plus 1-day recovery. The three treatment groups were then challenged with 10^5 *C. difficile* 630
 769 spores. B. *C. difficile* CFU/gram stool measured over time (N = 12-18 mice per time point) by serial
 770 dilutions. The black dashed horizontal line represents the limit of detection for the first serial dilution.
 771 For B and D, asterisks indicate time points where there was a significant difference ($P < 0.05$)
 772 between treatment groups by Kruskall-Wallis test with Benjamini-Hochberg correction for testing
 773 multiple time points. For B-D, each symbol represents a sample from an individual mouse and
 774

⁷⁷⁵ lines indicate the median value for each treatment group. C. PCoA of Bray-Curtis distances from
⁷⁷⁶ stool communities collected over time (day: $R^2 = 0.43$; group: $R^2 = 0.19$, Data Set S1, sheet 11).
⁷⁷⁷ Symbol transparency represents the day post-challenge of the experiment. For C-E, the B on the
⁷⁷⁸ day legend or days post-challenge X-axis stands for baseline and represents the sample that was
⁷⁷⁹ collected prior to any drug treatments. D. Shannon diversity in stool communities over time (Data
⁷⁸⁰ Set S1, sheet 12). E. Median relative abundances per treatment group for 6 out of the 14 genera
⁷⁸¹ that were affected by treatment, but recovered close to baseline levels by 7 days post-challenge
⁷⁸² (Fig. 3E, Data Set S1, sheets 13 and 14). Paired stool sample relative abundance values either
⁷⁸³ baseline and day 1 or baseline and day 7 were analyzed by paired Wilcoxon signed-rank test with
⁷⁸⁴ Benjamini-Hochberg correction for testing all identified genera. Only genera that were different
⁷⁸⁵ between baseline and 1-day post-challenge, but not baseline and 7-days post-challenge are shown.
⁷⁸⁶ The gray horizontal lines represents the limit of detection.








Figure 5.

788 **1-day PEG treatment post *C. difficile* challenge prolongs colonization regardless of**
789 **whether an FMT is also administered.** A. Setup of the experimental time line for experiments
790 with post-challenge PEG treated mice. There were a total of 4 different treatment groups. All mice
791 were administered 10 mg/kg clindamycin intraperitoneally (IP) 1 day before challenge with 10^{3-5}
792 *C. difficile* 630 spores. 1. Received no additional treatment (Clindamycin). 2. Immediately after
793 *C. difficile* challenge, mice received 15% PEG 3350 in the drinking water for 1 day. 3-4. 3-days
794 after challenge, mice received 1-day PEG treatment and then received either 100 microliters a
795 fecal microbiota transplant (3) or PBS (4) solution by oral gavage. Mice were followed through
796 15-30 days post-challenge (only the post-CDI 1-day PEG group was followed through 30 days
797 post-challenge). B. CFU/g of *C. difficile* stool measured over time via serial dilutions. The black line
798 represents the limit of detection for the first serial dilution. C-D. Shannon diversity (C) and richness
799 (D) in stool communities over time (Data Set S1, sheets 15 and 16). B-D. Each symbol represents
800 a stool sample from an individual mouse with the lines representing the median value for each
801 treatment group. Asterisks indicate time points with significant differences ($P < 0.05$) between
802 groups by the Kruskall-Wallis test with a Benjamini-Hochberg correction for testing multiple times
803 points. Colored rectangles indicates the 1-day PEG treatment period for applicable groups. The
804 data presented are from a total of 3 separate experiments.




806 **6. For 1-day PEG treatment post *C. difficile* challenge mice that also receive an FMT only**
807 **some bacterial genera were restored.** A. PCoA of Bray-Curtis distances from stool samples
808 collected over time as well as the FMT solution that was administered to one of the treatment
809 groups. Each circle represents an individual sample, the transparency of the circle corresponds
810 to day post-challenge. See Data Set S1, sheet 17 for PERMANOVA results. B. Median relative
811 abundances of 2 genera that were significantly different over multiple time points in mice that were
812 administered either FMT or PBS solution via gavage C. Median relative abundances of the top 6
813 out of 24 genera that were significant over multiple time points, plotted over time (see Data Set S1,
814 sheet 18 for complete list). For B-C, colored rectangles indicates the 1-day PEG treatment period
815 for applicable groups. Gray horizontal lines represent the limit of detection. Differences between
816 treatment groups were identified by Kruskal-Wallis test with Benjamini-Hochberg correction for
817 testing all identified genera. For pairwise comparisons of the groups (B), we performed pairwise
818 Wilcoxon comparisons with Benjamini-Hochberg correction for testing all combinations of group
819 pairs.



820


821 **Figure 7. Specific microbiota features associated with prolonged *C. difficile* colonization**
822 **in PEG treated mice.** A. Top ten bacteria that contributed to the random forest model trained on
823 5-day post-challenge community relative abundance data, predicting whether mice would still be
824 colonized with *C. difficile* 10 days post-challenge. The median (point) and interquartile range (lines)
825 change in AUROC when the bacteria were left out of the model by permutation feature importance
826 analysis. B. The median relative abundances of the top ten bacteria that contributed to the random
827 forest classification model at 5 days post-challenge . Red indicates the mice were still colonized

828 with *C. difficile* while blue indicates mice that cleared *C. difficile* 10 days post-challenge and the
829 black horizontal line represents the median relative abundance for the two categories. Each symbol
830 represents a stool sample from an individual mouse and the shape of the symbol indicates whether
831 the PEG-treated mice received a 5-day (Fig. 1-3), 1-day (Fig. 4) or post-challenge PEG (Fig. 5-6)
832 treatment. C. The median relative abundances of the 5 genera with greater than 1% median
833 relative abundance in the stool community over time. For B-C, the gray horizontal lines represents
834 the limit of detection.



835



836 **Figure 8. Schematic summarizing findings.** The gut microbiota of our C57Bl/6 mice is resistant
 837 to *C. difficile* but treatment with either the antibiotic, clindamycin, or the osmotic laxative, PEG
 838 3350, renders the mice susceptible to *C. difficile* colonization. Recovery of colonization resistance
 839 in clindamycin-treated mice is relatively straightforward and the mice clear *C. difficile* within 10
 840 days post-challenge. However, for mice that received either a 5-day PEG treatment prior to *C.*
 841 *difficile* challenge or a 1-day PEG treatment post-challenge recovery of colonization resistance was
 842 delayed because most mice were still colonized with *C. difficile* 10 days post-challenge. We found
 843 increased relative abundances of *Porphyromonadaceae* and *Lachnospiraceae* were associated
 844 with recovery of colonization resistance, while increased relative abundances of *Enterobacteriaceae*
 845 and *Bacteroides* were associated with prolonged *C. difficile* colonization.



846


847 **Figure S1. Microbiota dynamics post-challenge in the 5-day PEG treatment plus 10-day**

848 **recovery mice.** A. *C. difficile* CFU/g over time in the stool samples collected from 5-day PEG
849 treated mice that were allowed to recover for 10 days prior to challenge. Same data presented in
850 Fig. 1C, but the data for the other 3 treatment groups have been removed and each line represents
851 the CFU over time for an individual mouse. Mouse 10 was found dead 6 days post-challenge.
852 B. Relative abundances of eight bacterial genera from day 0 post-challenge onward in each of
853 the 10-day recovery mice. We analyzed samples from day 0 and day 8 post-challenge, which
854 represented the time points where mice were challenged with *C. difficile* and when the median
855 relative *C. difficile* CFU stabilized for the group using the paired Wilcoxon signed-rank test, but no
856 genera were significantly different after Benjamini-Hochberg correction (Data Set S1, sheet 5).



857
858 **Figure S2. PEG treatment still has a large impact on the mucosal microbiota 6 days**
859 **post-challenge** A. The relative abundances of the 10 bacterial genera that were significantly
860 different between treatment groups at 6 days post-infection in the cecum tissue (the relative
861 abundances of the 10 genera were also significantly different in the proximal and distal colon
862 tissues, Data Set S1, sheets 8, 9, and 10). Each symbol represents a tissue sample from an
863 individual mouse, the black horizontal lines represents the median relative abundances for each
864 treatment group. B. The relative abundance of *Peptostreptococcaceae* in the three types of tissue

865 sample communities over time. For A-B, the gray horizontal lines represent the limit of detection.



867 **Figure S3. *C. difficile* challenge does not enhance the disruptive effect of PEG on the**
 868 **microbiota.** A, D. PCoAs of the Bray-Curtis distances from the stool (A) and tissue (D) communities
 869 from mock- and *C. difficile*-challenged treatment groups. Each symbol represents a sample from an
 870 individual mouse with open and closed circles representing mock and *C. difficile*-challenged mice,
 871 respectively. B, E. Median Shannon diversity in stool (B) and tissue (E) communities collected over
 872 time. C, F. The median relative abundances of genera that were significantly different between
 873 the *C. difficile* challenged treatment groups in either the stool (Fig. 2E) or cecum tissue (Fig. 3C)

874 communities in the stool (C) and tissue (F) communities from mock- and *C. difficile*-challenged mice.
875 For B-F, the dashed and solid lines represent the median value for mock and *C. difficile*-challenged
876 mice, respectively. For E-F, tissues from mock-challenged clindamycin treated mice were only
877 collected 4 days post-challenge so there is no dashed line for this group.

878 **Data Set S1**

879 **Data Set S1, Sheets 1-19. Excel workbook with 19 sheets.**

880 **Data Set S1, Sheet 1. PERMANOVA results for the stool communities from mice in the 5-day PEG subset.**

882 **Data Set S1, Sheet 2. Shannon diversity analysis for the stool communities from mice in the 5-day PEG subset.**

884 **Data Set S1, Sheet 3. Genera with relative abundances impacted by PEG treatment based on stool communities of 5-day PEG treated mice.**

886 **Data Set S1, Sheet 4. Genera with relative abundances that vary between treatment groups in the stool communities from mice in the 5-day PEG subset.**

888 **Data Set S1, Sheet 5. Statistical analysis results for genera with relative abundances that varied in stool communities in the 5-day PEG plus 10-day recovery mice between the day 1 and day 8 time points.**

891 **Data Set S1, Sheet 6. Shannon diversity analysis for the cecum communities from mice in the 5-day PEG experiments.**

893 **Data Set S1, Sheet 7. PERMANOVA results for the tissue communities from mice in the 5-day PEG subset.**

895 **Data Set S1, Sheet 8. Genera with relative abundances that vary between treatment groups in the cecum communities from mice in the 5-day PEG esubset.**

897 **Data Set S1, Sheet 9. Genera with relative abundances that vary between treatment groups in the proximal colon communities from mice in the 5-day PEG subset.**

899 **Data Set S1, Sheet 10. Genera with relative abundances that vary between treatment groups in the distal colon communities from mice in the set of 5-day PEG subset.**

901 **Data Set S1, Sheet 11. PERMANOVA results for the stool communities from mice in the set**

902 **of 1-day PEG subset.**

903 **Data Set S1, Sheet 12. Shannon diversity analysis for the stool communities from mice in**
904 **the 1-day PEG experiments.**

905 **Data Set S1, Sheet 13. Genera with different relative abundances between the baseline and**
906 **day 1 time points in the 1-day PEG subset.**

907 **Data Set S1, Sheet 14. Genera with different relative abundances between the baseline and**
908 **day 7 time points in the 1-day PEG subset..**

909 **Data Set S1, Sheet 15. Shannon diversity analysis for the stool communities from mice in**
910 **the post-challenge PEG experiments.**

911 **Data Set S1, Sheet 16. Richness analysis for the stool communities from mice in the**
912 **post-challenge PEG experiments.**

913 **Data Set S1, Sheet 17. PERMANOVA results for the stool communities from mice in the**
914 **post-challenge PEG subset.**

915 **Data Set S1, Sheet 18. Genera with relative abundances that vary between treatment groups**
916 **in the stool communities from mice in the post-challenge PEG subset.**

917 **Data Set S1, Sheet 19. AUROC results for the 100 different seeds from each of the 3 models**
918 **tested.**